NO971349L - Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn - Google Patents

Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn

Info

Publication number: NO971349L
Authority: NO; Norway
Prior art keywords: men; pct; androgen deficiency; medicament; manufacture
Prior art date: 1994-09-22

Application number

NO971349A

Other languages

English (en)

Other versions

NO971349D0 (no

Inventor

Albert Radlmaier

Ursula-Friederike Habenicht

Friedmund Neumann

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-22

Filing date

1997-03-21

Publication date

1997-05-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6529877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO971349(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-03-21 Application filed by Schering Ag filed Critical Schering Ag

1997-03-21 Publication of NO971349D0 publication Critical patent/NO971349D0/no

1997-05-16 Publication of NO971349L publication Critical patent/NO971349L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines Containing Plant Substances (AREA)

NO971349A 1994-09-22 1997-03-21 Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn NO971349L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4435368A DE4435368A1 (de)	1994-09-22	1994-09-22	Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
PCT/EP1995/003733 WO1996009057A1 (de)	1994-09-22	1995-09-22	Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann

Publications (2)

Publication Number	Publication Date
NO971349D0 NO971349D0 (no)	1997-03-21
NO971349L true NO971349L (no)	1997-05-16

Family

ID=6529877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO971349A NO971349L (no)	1994-09-22	1997-03-21	Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn

Country Status (21)

Country	Link
US (1)	US5861389A (no)
EP (1)	EP0782450B1 (no)
JP (1)	JPH10505848A (no)
KR (1)	KR100387345B1 (no)
CN (1)	CN1104243C (no)
AT (1)	ATE241989T1 (no)
AU (1)	AU707997B2 (no)
BR (1)	BR9509155A (no)
CA (1)	CA2200195C (no)
CZ (1)	CZ76097A3 (no)
DE (2)	DE4435368A1 (no)
DK (1)	DK0782450T3 (no)
ES (1)	ES2199255T3 (no)
FI (1)	FI971207A0 (no)
HU (1)	HUT76981A (no)
MX (1)	MX9702170A (no)
NO (1)	NO971349L (no)
PL (1)	PL182909B1 (no)
PT (1)	PT782450E (no)
SK (1)	SK36397A3 (no)
WO (1)	WO1996009057A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19610645A1 (de) *	1996-03-06	1997-09-11	Schering Ag	Kombination von Dehydroepiandrosteron und Aromatasehemmern und Verwendung dieser Kombination zur Herstellung eines Arzeimittels zur Behandlung eines relativen und absoluten Androgenmangels beim Mann
US5972921A (en) *	1997-12-12	1999-10-26	Hormos Medical Oy Ltd.	Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO2001091744A1 (en)	2000-05-26	2001-12-06	Harry Fisch	Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) *	2000-05-26	2006-06-27	Harry Fisch	Methods of treating androgen deficiency in men using selective antiestrogens
US6607755B2 (en) *	2001-06-21	2003-08-19	Michael Donald Farley	Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
DK1411916T3 (da) *	2001-07-09	2008-12-15	Repros Therapeutics Inc	Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
US7737185B2 (en) *	2001-07-09	2010-06-15	Repros Therapeutics Inc.	Methods and compositions with trans-clomiphene
US7173064B2 (en) *	2001-07-09	2007-02-06	Repros Therapeutics Inc.	Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CA2469340A1 (en) *	2001-12-06	2003-06-19	Gtx Inc.	Treating muscle wasting with selective androgen receptor modulators
US6586417B1 (en)	2002-04-22	2003-07-01	Nutrisport Pharmacal, Inc.	Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans
WO2004064813A1 (en) *	2003-01-13	2004-08-05	Michael Donald Farley	Improvements in or relating to anti-aromatase composition
WO2004064814A1 (en) *	2003-01-13	2004-08-05	Michael Donald Farley	Improvements in or relating to anti-aromatase composition
US20040248989A1 (en)	2003-06-05	2004-12-09	Risto Santti	Method for the treatment or prevention of lower urinary tract symptoms
BRPI0513129A (pt) *	2004-07-14	2008-04-29	Repros Therapeutics Inc	método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo
NZ556499A (en) *	2005-02-04	2011-02-25	Repros Therapeutics Inc	Methods and materials with trans-clomiphene for the treatment of male infertility
JP5785680B2 (ja) *	2005-03-22	2015-09-30	リプロスセラピューティクスインコーポレイテッド	トランス−クロミフェン用の投与レジメン
RU2480207C2 (ru) *	2006-05-22	2013-04-27	Хормос Медикал Лтд.	Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы
CN102940619A (zh)	2007-10-16	2013-02-27	利普生物药剂公司	用于治疗代谢综合征的珠氯米芬
CN102335269B (zh) *	2007-11-21	2013-06-19	客乐谐制药株式会社	芳香酶抑制剂
US20090215733A1 (en) *	2008-02-26	2009-08-27	Michael Charles Scally	Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
CA2673461C (en) *	2009-08-07	2011-07-26	Bruce W. Kneller	5.alpha.-androstane-3,6,17-trione (kneller's trione) and methods of use therefor
US20090306031A1 (en) *	2009-08-07	2009-12-10	Kneller Bruce W	5alpha-ANDROSTANE-3,6,17-TRIONE (KNELLER'S TRIONE) AND METHODS OF USE THEREFOR
UA113291C2 (xx)	2011-08-04	2017-01-10		Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) *	2011-08-09	2013-02-14	Adams Kenneth W	Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
KR20140071358A (ko) *	2011-09-08	2014-06-11	노파르티스 아게	생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도
CN102641502A (zh) *	2012-04-25	2012-08-22	中国农业大学	芳香酶抑制剂的新用途
HK1216502A1 (zh)	2012-11-02	2016-11-18	Repros Therapeutics Inc.	用於癌症治療的反式-克羅米芬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4289762A (en) *	1980-06-27	1981-09-15	Merrell Dow Pharmaceuticals Inc.	10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
US4322416A (en) *	1980-06-27	1982-03-30	Merrell Dow Pharmaceuticals Inc.	10-Alkynyl steroids
EP0100566B1 (en) *	1982-07-14	1986-02-19	Akzo N.V.	Novel 19-thio-androstane derivatives
DE3322285A1 (de) *	1983-06-18	1984-12-20	Schering AG, 1000 Berlin und 4709 Bergkamen	1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3539244A1 (de) *	1985-11-01	1987-05-07	Schering Ag	1-methyl-15(alpha)-alkyl-androsta- 1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
GB8531745D0 (en) *	1985-12-24	1986-02-05	Erba Farmitalia	10beta-alkynyl-4-9(11)-estradiene derivatives
GB8615092D0 (en) *	1986-06-20	1986-07-23	Erba Farmitalia	Androst-4-ene-317-diones
DE3705990A1 (de) *	1987-02-20	1988-09-01	Schering Ag	1-methyl-15(alpha)-(1-oxyalkyl)-androsta-1,4-dien- 3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE3926365A1 (de) *	1989-08-04	1991-02-07	Schering Ag	Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln
GB9226620D0 (en) *	1992-12-21	1993-02-17	Fujisawa Pharmaceutical Co	A new compound fr 901537,production thereof and use thereof

1994
- 1994-09-22 DE DE4435368A patent/DE4435368A1/de not_active Withdrawn
1995
- 1995-09-22 CN CN95195216A patent/CN1104243C/zh not_active Expired - Fee Related
- 1995-09-22 KR KR1019970701850A patent/KR100387345B1/ko not_active Expired - Fee Related
- 1995-09-22 DE DE59510714T patent/DE59510714D1/de not_active Expired - Fee Related
- 1995-09-22 JP JP8510608A patent/JPH10505848A/ja active Pending
- 1995-09-22 DK DK95934094T patent/DK0782450T3/da active
- 1995-09-22 WO PCT/EP1995/003733 patent/WO1996009057A1/de not_active Ceased
- 1995-09-22 CA CA002200195A patent/CA2200195C/en not_active Expired - Fee Related
- 1995-09-22 AT AT95934094T patent/ATE241989T1/de not_active IP Right Cessation
- 1995-09-22 SK SK363-97A patent/SK36397A3/sk unknown
- 1995-09-22 MX MX9702170A patent/MX9702170A/es not_active IP Right Cessation
- 1995-09-22 US US08/809,582 patent/US5861389A/en not_active Expired - Fee Related
- 1995-09-22 PL PL95319299A patent/PL182909B1/pl not_active IP Right Cessation
- 1995-09-22 EP EP95934094A patent/EP0782450B1/de not_active Expired - Lifetime
- 1995-09-22 CZ CZ97760A patent/CZ76097A3/cs unknown
- 1995-09-22 ES ES95934094T patent/ES2199255T3/es not_active Expired - Lifetime
- 1995-09-22 PT PT95934094T patent/PT782450E/pt unknown
- 1995-09-22 HU HU9701697A patent/HUT76981A/hu unknown
- 1995-09-22 FI FI971207A patent/FI971207A0/fi not_active IP Right Cessation
- 1995-09-22 AU AU36518/95A patent/AU707997B2/en not_active Ceased
- 1995-09-22 BR BR9509155A patent/BR9509155A/pt not_active Application Discontinuation
1997
- 1997-03-21 NO NO971349A patent/NO971349L/no unknown

Also Published As

Publication number	Publication date
CN1158570A (zh)	1997-09-03
CN1104243C (zh)	2003-04-02
SK36397A3 (en)	1997-08-06
EP0782450A1 (de)	1997-07-09
DE59510714D1 (de)	2003-07-10
KR100387345B1 (ko)	2003-08-30
US5861389A (en)	1999-01-19
PL319299A1 (en)	1997-08-04
WO1996009057A1 (de)	1996-03-28
DE4435368A1 (de)	1996-03-28
KR970706002A (ko)	1997-11-03
JPH10505848A (ja)	1998-06-09
PT782450E (pt)	2003-09-30
PL182909B1 (pl)	2002-04-30
NO971349D0 (no)	1997-03-21
CZ76097A3 (en)	1997-07-16
EP0782450B1 (de)	2003-06-04
FI971207L (fi)	1997-03-21
ATE241989T1 (de)	2003-06-15
BR9509155A (pt)	1997-10-14
FI971207A7 (fi)	1997-03-21
CA2200195C (en)	2008-04-22
CA2200195A1 (en)	1996-03-28
AU707997B2 (en)	1999-07-29
HUT76981A (hu)	1998-01-28
AU3651895A (en)	1996-04-09
ES2199255T3 (es)	2004-02-16
DK0782450T3 (da)	2003-08-18
FI971207A0 (fi)	1997-03-21
MX9702170A (es)	1998-04-30

Publication	Publication Date	Title
NO971349L (no)	1997-05-16	Anvendelse av aromatiske inhibitorer ved fremstilling av et legemiddel for behandling av en relativ androgenmangel hos menn
McCaffrey et al.	1977	Management of epistaxis in hereditary hemorrhagic telangiectasia: review of 80 cases
NO20003546L (no)	1995-06-16	Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
Perlroth et al.	1965	Oral contraceptive agents and the management of acute intermittent porphyria
BR9806060A (pt)	1999-08-31	Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
IL114446A0 (en)	1995-11-27	New pharmaceutical preparation for pain management
CA2467222A1 (en)	2003-05-22	Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
BG105302A (en)	2001-11-30	Means for improving cognition
BR9713921A (pt)	2000-03-21	Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
IL159241A0 (en)	2004-06-01	Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
PL356847A1 (en)	2004-07-12	Hormonal composition based on a progesterone and an oestrogen and use thereof
Seehusen et al.	2007	Postpartum labial adhesions
LV10839A (lv)	1995-10-20	Arstniecibas lidzeklis lipidu un holesterina vielmainas traucejumu profilaksei un arstesanai so traucejumu profilakses un arstesanas panemiens
Silberstein et al.	2000	Migraine, menopause and hormonal replacement therapy
Mössner	1993	Is there a place for pancreatic enzymes in the treatment of pain in chronic pancreatitis?
HUP0101005A2 (hu)	2001-08-28	Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
WO2006041939A3 (en)	2007-05-03	Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
BR0208920A (pt)	2004-04-20	Inibidor de aromatase em dose única para tratamento de infertilidade
JP2004529924A5 (no)	2006-01-05
EP1240901A4 (en)	2005-01-12	MEDICINAL COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF DISEASES BASED ON ABNORMAL BLOOD COAGULATION
DK0648117T3 (da)	1998-02-23	Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
Pagliaro et al.	1993	Carbamazepine-induced Stevens-Johnson syndrome
AU2003285426A8 (en)	2004-05-13	Use of tenatoprazole for the treatment of gastroesophageal reflux
EP0968717B1 (fr)	2006-06-07	Préparation sous forme galénique simple visant à limiter les effects induits durant la ménopause et postérieurement et traitement avec cette préparation
RU2201233C1 (ru)	2003-03-27	Способ профилактики хронических циститов в период менопаузы